AML 16: Evalution of the prognostic impact and optimal use of immunophenotypic monitoring of residual disease in patients with acute myeloid lukaemia recruited to AML 16

Project Details

Short titleAML 16: Evalution of the prognostic impact and optimal use of immunophenotypic monitoring of residual disease in patients with acute myeloid lukaemia recruited to AML 16
StatusFinished
Effective start/end date1/04/07 → 31/03/12

Funding

  • Cancer Research UK